Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28752388 | 0.82 | — | — | |
| SCHEMBL5148556 | 0.79 | — | — | |
| SCHEMBL5147595 | 0.77 | MEN1 (0.35) | — | |
| SCHEMBL5151713 | 0.74 | NCF1 (0.31) | — | |
| SCHEMBL5147545 | 0.67 | CAPN1 (0.31) | — | |
| SCHEMBL9321175 | 0.63 | MTNR1A (0.47) | KDM4ENR4A2MAPK1SMN1; SMN2 | |
| SCHEMBL30547297 | 0.62 | SIRT2 (0.45) | KDM4E | |
| SCHEMBL5150230 | 0.62 | RIPK2 (0.33) | — | |
| SCHEMBL10616929 | 0.62 | KMT2A (0.37) | KDM4ESMN1; SMN2 | |
| SCHEMBL5148524 | 0.62 | ALDH1A1 (0.35) | KDM4EMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
| CN-1522259-A | Cephem compounds | ����ҩƷ��ҵ��ʽ���� | 2004-08-18 | — | — | CN | disclosed |
| EP-1392704-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090364-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | KDM4E 2903/4885NR4A2 4399/4885ABHD6 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.